Omeros extending compassionate use for pediatric patient no longer requiring dialysis
Omeros announced that, following physician request, it will provide continued supply of OMS721 for a pediatric patient with hematopoietic stem cell transplant-associated thrombotic microangiopathy who is currently receiving the drug under the company’s compassionate use program. December 06, 2016